Medovex's DenerveX Scheduled Cases in Germany

Medovex (NASDAQ:MDVX) announced the first cases in Germany for the DenerveX system have been scheduled.
As quoted in the press release:

On July 26, 2017, Dr. Martin Deeg will perform three cases in Stuttgart. The following week on July 31, 2017, Chief Surgeon Dr. Jan Spiller will perform three additional cases in Bremen-Stenum along with Dr. Ritter-Lang. Both Dr. Deeg and Ritter-Lang are members of the Company’s European Medical Advisory Board.
The Company recently announced it had completed first human use cases for the DenerveX System in Manchester, England with very encouraging initial procedural success. The Company anticipates performing up to as many as 30 plus procedures by the end of August.
The DenerveX System recently received CE Mark approval and clearance for commercialization in the European countries and offers a unique way to perform a Facet Joint Syndrome treatment.
Jarrett Gorlin, Medovex CEO stated, “We are pleased to announce further progress towards delivering on our goal of ‘proof of principle’ in the adoption of the technology in this very sizable market. With the DenerveX System, we can offer surgeons and pain management specialists the ability to attain precise treatment of the Facet Joint pain. The DenerveX treatment uses ‘Rotacapsulation™,’ a combination of high heat and rotational capsular tissue shaving, in a minimally invasive posterior procedure for the treatment of Facet Joint Syndrome. The DenerveX System offers an alternative to existing treatments that only provide temporary relief.”

Click here to read the full press release.

Source: www.marketwired.com